Preventing heart disease and cancer. What randomized, primary-prevention studies show.
Several chemical agents appear to be useful in primary prevention of CAD and cancer. Randomized trials have found that in specific patient subgroups, tamoxifen and raloxifene decreased the occurrence of breast cancer, and lovastatin and aspirin decreased the frequency of CAD events. Secondary analysis of randomized primary-prevention studies has supported the use of vitamin E and selenium in cancer prevention.
Lush
D T
DT
Primary Care Unit, MCP Hahnemann University, Philadelphia, PA, USA.
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000517:prevention & control; D003327:Coronary Disease / Q000517:prevention & control*; D005260:Female; D006331:Heart Diseases / Q000517:prevention & control*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011322:Primary Prevention; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012643:Selenium / Q000627:therapeutic use; D013629:Tamoxifen / Q000627:therapeutic use; D014810:Vitamin E / Q000627:therapeutic use
D000970:Antineoplastic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D013629:Tamoxifen; D014810:Vitamin E; D020849:Raloxifene Hydrochloride; D012643:Selenium; D001241:Aspirin